[1] |
Mogami R,Goldenberg T,de Marca PG,et al.Pulmonary infection caused by Mycobacterium kansasii:findings on computed tomography of the chest[J].Radiol Bras,2016,49(4):209-213.
|
[2] |
He GL,Chang YJ,Xu LP,et al.Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation[J].J Thorac Dis,2016,8(8):2219-2225.
|
[3] |
Ramsay KA,Sandhu H,Geake JB,et al.The changing prevalence of pulmonary infection in adults with cystic fibrosis:A longitudinal analysis[J].J Cyst Fibros,2016,3(16): 30567.
|
[4] |
Haste L,Hulland K,Bolton S,et al.Development and characterization of a long-term murine model of Streptococcus pneumoniae infection of the lower airways[J].Infect Immun,2014,82(8):3289-3298.
|
[5] |
蔡凯旋.舒普深治疗小儿肺炎的临床效果分析[J].深圳中西医结合杂志,2015,25(3):82-83.
|
[6] |
Virchow JC,Rodriguez-Roisin R,Papi A,et al.A randomized,double blinded,double-dummy efficacy and safety study of budesonide-for-moterol Spiromax compared to budesonideformoterolTurbuhalerinadultsandadolescentswithpersistent asthma[J].BMC Pulm Med,2016,17(16):42.
|
[7] |
马花平.头孢哌酮钠/舒巴坦钠(舒普深)治疗老年人肺部感染的临床分析[J].中国当代医药,2016,23(24):115-117.
|
[8] |
郭利明,曾小飞,金家贵,等.拜复乐治疗细菌感染性疾病的双盲随机对照研究[J].西部医学,2010,22(6):1014-1016.
|
[9] |
李志芳,段成城,董丽妍,等.老年心力衰竭肺部感染患者舒巴坦应用的效果分析[J].中华医院感染学杂志,2016,26(8):1767-1769.
|
[10] |
陈映红,熊涛.不同炎性指标评估重症肺炎患者病情变化的临床对比研究[J].检验医学与临床,2017,14(7):926-928.
|
[11] |
高爽,张放,马帅,等.弥散性血管内凝血评分系统评分联合C反应蛋白对重症肺炎患者急性肾损伤的预测价值[J].中国急救医学,2015,4(12):1122-1126.
|
[12] |
龙鼎,喻莉,杨军辉,等.替加环素联合头孢哌酮舒巴坦钠治疗广泛耐药鲍曼不动杆菌老年肺部感染疗效观察[J].中华实用诊断与治疗杂志,2016,30(5):512-514.
|
[13] |
李秀红,李波.舒普深对下呼吸道感染的抗菌效果及耐药趋势[J].中国药业,2013,22(8):46-47.
|
[14] |
宋丽芹,李鑫,郑录.舒普深联合左氧氟沙星治疗哮喘并发肺部感染的疗效分析[J].现代生物医学进展,2017,17(9):1729-1731.
|
[15] |
朱建俊,胡志伟,钱一龙.莫西沙星联合小剂量激素对高龄重症呼吸机肺炎患者的临床疗效及免疫功能的影响[J].中国生化药物杂志,2016,36(9):58-61.
|
[16] |
王松芝.临床常见感染菌对舒普深的耐药性分析[J].临床和实验医学杂志,2013,12(6):469-470.
|